

• **Name:** Susanne Saußebe

• **Current Position:**

Head, CML Excellence Center, III. Medizinische Klinik, Hematology and
Oncology, University of Mannheim, Mannheim, Germany

• **Country:** Germany

• **Educational Background:**

- Studied of Medicine the University of Heidelberg and Specialized in Internal Medicine and Hematology/Oncology.
- Completed her thesis in the laboratory of Prof Dr Hehlmann and made her habilitation in Internal Medicine in 2013.
-

• **Professional Experiences:**

- 2017, Professor of the University of Heidelberg.
- Present, Leader of the CML Excellence Center, Mannheim including the molecular laboratory and the Study Centre of the German CML Study Group
- Acting as chief resident of the policlinic at the III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg .
- Project Leader in EUTOS (European treatment and Outcome Study of CML) and in the E-MPN network (European network for MPN)

• **Professional Organizations:**

- Active member in the ELN CML Working Party
- Member of the Scientific Program Committee of EHA

• **Main Scientific Publications:**

1. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pffirmann M, Mahon FX; EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a

- prospective, multicentre, non-randomised, trial. *Lancet Oncol.* 2018 Jun;19(6):747-757
2. Hochhaus A, **Saussele S**, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2017 Jul 1;28(suppl_4):iv41-iv51. doi: 10.1093/annonc/mdx219.
 3. Kim DW, Saussele S, Williams LA, Mohamed H, Rong Y, Zyczynski T, Pinilla-Ibarz J, Abruzzese E. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. *Ann Hematol.* 2018 Aug;97(8):1357-1367

Susanne Saußebe studied medicine at the University of Heidelberg and specialized in Internal Medicine and Hematology/Oncology. She completed her thesis in the laboratory of Prof Dr Hehlmann and made her habilitation in Internal Medicine in 2013. In 2017, she was appointed as professor of the University of Heidelberg. Currently, she is the leader of the CML Excellence Center in Mannheim including the molecular laboratory and the Study Centre of the German CML Study Group. She is acting as chief resident of the policlinic at the III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg. Prof. Saußebe is also active as a project leader in EUTOS (European treatment and Outcome Study of CML) and in the E-MPN network (European network for MPN) and as active member in the ELN CML Working Party. Additionally she is member of the Scientific Program Committee of EHA.